13 May 2022

TruSpine Technologies plc
("**TruSpine**" or the "**Company**")

Appointment of Director

TruSpine Technologies plc, (AQSE: TSP) the medical device company focused on the development of its pioneering "screwless" spinal (vertebral) stabilisation systems announces that, further to the announcement dated 28 April 2022, Mr. Vincent Proffitt ("Vince") has been appointed as Non-Executive Director of the Company with immediate effect.

Vince is a veteran of the United States Air Force ("USAF") where he spent five years of his service as an Intelligence Officer ("IO"). In his last Active Duty assignment, he was responsible for the management and strategic planning of the USAF IO Officer training course, and directly supervised over 40 instructors and managed over 1150 hours of training syllabus. Following his time in the USAF, Vince joined Medtronic, a healthcare technology solutions company, as a sales representative where he became one of the top 10 sales reps in the country for surgical products as a President's Club inductee. He founded Spartan Medical in 2008 to supply a broad and thorough product line dedicated to best-in-class technologies. He is nationally recognised as a medical device expert, a successful business owner, and an industry thought leader.

Save as set out below, no further information regarding Mr. Vince Proffitt is required to be disclosed pursuant to Rule 4.9 of the AQSE Growth Market Access Rulebook.

Mr. Vincent Anthony Proffitt (aged 44) has held the following current and former directorships within the past five years:

Current Directorships	**Directorships in the past 5 years**
Proffitt Brothers Enterprises, LLC	JBH Innovation, LLC
Proffitt Brothers Foundation, Inc	
Proffitt Brothers Investments LLC	
Spartan Medical Inc	
Sure Retractors Inc	

Mr. Vince Proffitt is beneficially interested in 1,000,000 warrants exercisable at 20 pence per share over new ordinary shares in the Company through his wholly-owned company, Proffitt Brothers Investments LLC. A further 1,000,000 warrants will be issued to Proffitt Brothers Investments LLC, following the payment of Tranche 3 of the Funding Agreement announced 28 April 2022.

There is no further information to be disclosed pursuant to Rule 4.9 of the AQSE Growth Market Access Rulebook.

Ian Roberts, CEO of TruSpine, commented: "*The Board and I are delighted to welcome Vince to the Company at this exciting stage of its development. His specific background in the US healthcare environment and in-depth knowledge of the sector are instrumental, and mean he is excellently placed to serve in this role at an important time for TruSpine. We look forward to capitalising on his expertise and for the value he will bring to the team.*"

This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

Enquiries:

TruSpine Technologies Plc Tel: +44 (0)20 3638 5025
Ian Roberts, CEO

Cairn Financial Advisers LLP (AQSE Corporate Adviser) Tel: +44 (0)20 7213 0880
Liam Murray / Ludovico Lazzaretti

Oberon Capital (Broker) Tel: +44 (0)20 3179 5300
Mike Seabrook / Chris Crawford

Walbrook PR (Financial PR & IR) Tel: +44 (0) 20 7933 7870 or +44 (0) 7876 741 001
Anna Dunphy truspine@walbrookpr.com